ClinicalTrials.gg
WithdrawnNCT01390324AtenéiaUpdated Oct 19, 2016

Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine

A Phase 3 interventional study of Fixed-dose combination of naratriptan+naproxen and Naratriptan in Migraine and Headache, sponsored by Ache Laboratorios Farmaceuticos S.A.. Withdrawn. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-10-19.

Sponsored by Ache Laboratorios Farmaceuticos S.A. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether a fixed-dose combination of naratriptan + naproxen is effective compared each monotherapy for the acute treatment of migraine.

02

Conditions studied

  • Migraine
  • Headache

Keywords

  • Migraine
  • Naratriptan
  • Naproxen
03

In context

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 341 are open to participants now.

Browse Migraine Disorders studies →

Lead sponsor

Ache Laboratorios Farmaceuticos S.A. is the lead sponsor of 36 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patient, age in the range of 18-65 years inclusive that has onset of migraine before age 50;
  • Patient has at least a 3-month history of migraine with or without aura according to the ICHD-II, 2004, IHS (International Headache Society) criteria;
  • Patients experienced an average migraine headache frequency of 2-6 moderate or severe attacks per month in the last 03 months prior to screening visit;
  • Patients able to distinguish his/her migraine attacks from any other types of headaches;
  • Patients able to understand and consent to participate in this clinical study, expressed by signing the (IC).

Exclusion criteria

Exclusion Criteria:

  • History of more than 6 migraine attacks/month in the last 03 months prior to screening visit;
  • History of non-migraine headache frequency ≥ 15 days/month in each of the 3 months prior to screening.
  • History of following migraine variants, according to the ICHD-II, 2004, IHS (International Headache Society): basilar migraine, aura without headache, familial hemiplegic migraine, sporadic hemiplegic migraine or aura with non-migraine headache;
  • If female of , has a negative urine pregnancy test at Visit 0 and uses, or agrees to use, for the duration of the study, a medically acceptable form of as determined by the investigator;
  • Woman in pregnancy or lactation period;
  • History of epilepsy or psychiatric condition that may affect the compliance of the treatment;
  • Patients in acupuncture treatment for the symptoms of migraine attacks;
  • Suffers from cardiovascular disease (ischemic heart disease, including angina pectoris, myocardial infarction, documented silent ischemia, or with Prinzmetal's angina) or has symptoms of ischemic heart disease;
  • History of cerebrovascular pathology including stroke and/or ;
  • History of allergic reactions to naproxen preparations, including subjects in whom aspirin or other NSAID drugs induce the syndrome of asthma, rhinitis, nasal polyps or urticaria;
  • Diagnosis of renal or hepatic failure;
  • Has significant (as determined by the investigator) cardiovascular risk factors that may include uncontrolled high blood pressure, women, males over 40 years old, hypercholesterolemia, obesity, diabetes mellitus, smoking, or a family history of cardiovascular disease in a 1st degree relative.
  • Patients who have stopped or changed the dosage of the preventive treatment of migraine in the last 2 weeks prior the screening visit (V0), including the use of calcium channel blockers, tricyclic antidepressants, beta blockers or serotonergic medications for any other indications;
  • Use of prohibited medicine as shown in 9.3 item of this protocol;
  • Inability to understand and report the categorical scale debilitating functional of study or symptoms diary;
  • Has abused, in the opinion of the Investigator, any of the following drugs, currently or within the past 2 years: opioids, alcohol, barbiturates, benzodiazepine, cocaine or abuse of drugs for migraine treatment including narcotics ergotamines headache in the past 03 months;
  • , intolerance, or to the use of naratriptan or naproxen, any of its components;
  • Hypersensitivity, intolerance, or contraindication to the use of sulfonamides;
  • History of ≤ 5 years or > 5 years without documentation of remission / cure, for example, melanoma, leukemia, lymphoma, myeloproliferative disorders and renal cell carcinoma of any duration. Exception: Subjects with basal cell skin cancers, squamous cell, and cervical cancer in situ may be eligible;
  • Participation in last one year of clinical protocols, unless it can be direct benefit to patient;
  • Any finding of clinical observation (anamnesis and physical exam) laboratory abnormality (eg, blood glucose, blood count), disease (for example, liver, cardiovascular system, lung) or therapy that, in opinion of the investigator, may endanger the patient or interfere with the endpoints of study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Fixed-dose combination of naratriptan+naproxen

    Fixed-dose combination of naratriptan+naproxen

    Drug: Fixed-dose combination of naratriptan+naproxen

  • Active comparator
    Naratriptan

    Naratriptan

    Drug: Naratriptan

  • Active comparator
    Naproxen

    Naproxen

    Drug: Naproxen

Interventions

  • DrugFixed-dose combination of naratriptan+naproxen

    Tablets containing naratriptan 2,5 mg + naproxen 500 mg

  • Tablets containing naratriptan 2,5 mg

  • Tablets containing naproxen 500 mg

06

What researchers measure

Primary outcomes

  1. Headache relief 2 hours after dosing, without use of rescue medication.

    Participants were evaluated (self-assessment) for pain intensity by using a 4-point rating scale: 0=none, 1=mild, 2=moderate, and 3=severe.

    Time frame: 2 hours after single dose of double-blind treatment

Secondary outcomes

  1. Headache relief 4 hours after dosing, without use of rescue medication

    Time frame: 4 hours after single dose of double-blind treatment

  2. Sustained headache relief over 24 hours, without use of rescue medication

    Time frame: 24 hours after single dose of double-blind treatment

  3. Pain-free response 2 and 4 hours after dosing, without use of rescue medication

    Time frame: 2 and 4 hours after single dose of double-blind treatment

  4. Sustained pain-free response over 24 hours, without use of rescue medication

    Time frame: 24 hours after single dose of double-blind treatment

  5. Freedom from photophobia, phonophobia and nausea 2 and 4 hours after dosing, without use of rescue medication

    Time frame: 2 and 4 hours after single dose of double-blind treatment

  6. Sustained freedom from photophobia, phonophobia and nausea from 2 through 24 hours after dosing, without use of rescue medication

    Time frame: 2 through 24 hours after single dose of double-blind treatment

  7. Proportion of subjects who used rescue medication between 2 and 24 hours after dosing, at least once

    Time frame: 2 and 24 hours after single dose of double-blind treatment

  8. Safety descriptive about occurence of adverse events, evaluation of results of general physical examination.

    Time frame: Collection of safety data throughout the whole study period

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2011
First posted
Jul 11, 2011
Start
Dec 2011
Primary completionActual
Mar 2012
CompletionActual
Mar 2012
Last update
Oct 19, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01390324
Responsible party
Sponsor
First posted
Jul 11, 2011
Start date
Dec 2011
Primary completion
Mar 2012
Completion
Mar 2012
Last update
Oct 19, 2016

Study contacts

Deusvenir S Carvalho
principal investigator · Federal University of São Paulo

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion